The effects of dose, route of administration, drug scheduling and MDR-1 gene transfer on the genotoxicity of etoposide in bone marrow

Leukemia

Volumn 14, Issue 10, 2000, Pages 1796-1802

  Turner, S D ^a   Rafferty, J A ^a   Fairbairn, L J ^a   Ashby, J ^b   Tinwell, H ^b   Eckert, H G ^c   Baum, C ^c   Lashford, L S ^a,d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^d CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Bone marrow; Etoposide dose schedule; Gene transfer; Micronucleus; Multidrug resistance

Indexed keywords

ALCOHOL; BENZYL ALCOHOL; CITRIC ACID; CLASTOGEN; DRUG VEHICLE; ETOPOSIDE; FLUOROURACIL; MACROGOL; POLYSORBATE 80; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CELL COUNT; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EXPOSURE; DRUG POTENCY; ERYTHROCYTE; FEMALE; FRACTIONATION; GENE EXPRESSION; GENE TRANSFER; GENOTOXICITY; HEMATOPOIETIC SYSTEM; MALE; MICRONUCLEUS; MICRONUCLEUS TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS;

EID: 0033810378     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401810     Document Type: Article

References (42)

1. General principles of chemotherapy
2. Non-intercalative antitumour drugs interfere with the breakage reunion of mammalian DNA topoisomerase II
3. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage
4. Topoisomerase II mediated DNA breaks and cytotoxicity in relation with proliferation and the cell cycle in NIH3T3 fibroblasts and L1210 leukaemia cells
5. Sister chromatid exchanges, chromosomal aberrations and cytotoxicity produced by antitumour topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cells
6. Mechanism of epipodophyllotoxin-induced cell death in poly(adenosine diphosphate-ribose) synthesis-deficient V79 Chinese hamster cell lines
7. HRX involvement in de novo and secondary leukaemias with diverse chromosome 11q23 abnormalities
8. Acute non-lymphocytic leukaemia following etoposide and cisplatin combination chemotherapy for advanced non-small cell carcinoma of the lung
9. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin and bleomycin for germ-cell tumours
10. Secondary leukaemia associated with a conventional dose of etoposide: Review of serial germ cell tumour protocols
11. Acute non-lymphocytic leukaemia in germ cell tumour patients treated with etoposide-containing chemotherapy
12. Epipodophyllotoxins, alkylating agents and radiation risk of secondary leukaemia after childhood cancer
13. Acute myeloid leukaemia in children treated with epipodophyllotoxins for acute lymphoblastic leukaemia
14. 6-alkylguanine-DNA-alkyl transferase in HeLa cells by cisplatin
15. 6-alkylguanine-DNA-alkyltransferase in limiting nitrosourea-induced sister chromatid exchanges in proliferating human lymphocytes
16. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute non-lymphocytic leukaemia: Further evidence for characteristic abnormalities of chromosomes No. 5 and 7
17. Secondary acute myeloid leukaemia in children with acute lymphoblastic leukaemia treated with etoposide
18. Granulocyte colony-stimulating factor enhances bone marrow stem cell damage caused by repeated administration of cytotoxic agents
19. Chemoprotection of normal tissues by transfer of drug resistance genes
20. The micronucleus test
21. Genetic chemoprotection of bone marrow from the dose-limiting toxicities of chemotherapy
22. Comparison of acridine orange and giesma stains in several mouse bone marrow studies including a triple dose experiment
23. The micronucleus assay with mouse peripheral blood reticulocytes using acridine orange coated slides
24. High dose multidrug resistance in primary human hematopoietic cells transduced with optimized retroviral vectors
25. Long-term in vitro correction of α-iduronidase deficiency (Hurler syndrome) in human bone marrow
26. 6-alkylguanine-DNA alkyltransferase
27. Sex determination in single mouse blastomeres by polymerase chain reaction
28. Phase II study of 21 day oral etoposide in children. New agents group of the United Kingdoms Childrens Cancer Study Group (UKCCSG)
29. The activity of 10, 14 and 21 day oral schedules of single agent etoposide in previously untreated patients with extensive SCLC
30. A simple technique for quantitation of low levels of DNA damage in individual cells
31. Detection of chemical mutagens using MutaMouse: A transgenic mouse model
32. Potent clastogenicity of the human carcinogen etoposide to the mouse bone marrow and mouse lymphoma L5178Y cells: Comparison to Salmonella responses
33. Etoposide and teniposide: In vitro and in vivo genotoxicity studies
34. Bioavailability, pharmacokinetics and clinical effects of an oral preparation of etoposide
35. Single vs multiple dosing in the micronucleus test: The summary of the fourth collaborative study by CSGMT/JEMS.MMS
36. Simulation study of the effects of multiple treatments in the mouse bone marrow micronucleus test
37. Response of cellular DNA topoisomerases to induction of full length E2F-1/DP-1 transcription factor
38. Physiological regulation of eukaryotic topoisomerase II
39. Radiation-induced genomic instability in haemopoietic cells
40. Multiple drug resistance, the MDR gene, and the law of maximum perversity as it applies to oncology: An hypothesis